February 1, 2026
Warren Foust
c/o STAAR Surgical Company 25510 Commercentre Drive Lake Forest, California 92630
Re: Interim Co-CEO Letter Agreement Dear Warren:
This letter agreement (“Agreement”) sets forth certain terms and conditions of your appointment as Interim
Co-Chief Executive Officer (“Interim Co-CEO”) of STAAR Surgical Company (the “Company”) reporting to the Board of Directors of the Company (the “Board”). The terms of this Agreement are in addition to the terms and conditions of your offer letter with the Company, dated March 24, 2023, the STAAR Surgical Company Severance Agreement by and between you and the Company dated July 18, 2023 (the “Severance Agreement”), the STAAR Surgical Company Change in Control Agreement by and between you and the Company dated July 19, 2023 (the “CIC Severance Agreement”), and any outstanding Awards (as defined in the Company Amended and Restated Omnibus Equity Incentive Plan, as amended from time to time (the “Plan”)) that have been granted to you under the Plan, in each case, which shall remain in full force and effect and continue to govern your employment except as set forth herein. Unless otherwise defined herein, capitalized terms shall have the same meanings assigned to such terms in the Severance Agreement.
The Company shall appoint you and you shall assume the role of Interim Co-CEO on February 1, 2026 (the “Start Date”) and act as Interim Co-CEO until the earlier to occur of (i) August 1, 2026 and (ii) the date on which the Company makes a public announcement of the appointment of a Chief Executive Officer (“CEO”) of the Company (hereinafter the “Term”).
Subject to your commencement as Interim Co-CEO, the Company shall grant you a one-time award under the Plan, of Restricted Stock Units (as defined in the Plan), effective as of February 1, 2026, with a grant date value of $375,000 (the “Equity Grant”). The Equity Grant shall vest on August 1, 2026, subject to your continued employment with the Company through the vesting date; provided that if the Company terminates your service without Cause (excluding due to death or Disability) or you resign for Good Reason prior to August 1, 2026, the Restricted Stock Units shall accelerate and vest. Notwithstanding anything in here to the contrary, the Equity Grant shall be subject to the terms and conditions of the Equity Grant agreement, provided by the Company, and the Plan.
In the event the Company does not offer you the position of CEO prior to the end of the Term and you resign from the Company within five (5) days of the end the Term, such resignation shall be deemed “Good Reason” for purposes of your Severance Agreement and CIC Severance Agreement without regard to the notice and cure period in the applicable “Good Reason” definition in the such agreements (the “Interim Co-CEO Good Reason Event”). Following the end of the Term, unless you are appointed CEO or the Interim Co-CEO Good Reason Event has occurred (including your termination of employment with the Company within five (5) days of the end of the Term), you will continue your role as President and Chief Operating Officer of the Company and acknowledge and agree that the end of the Term and your removal as Interim Co-CEO shall not constitute “Good Reason” under the Severance Agreement or CIC Severance Agreement. For avoidance of doubt, during the Term you shall remain eligible for merit increases, benefits and awards under all programs in which you currently participate, subject to the eligibility criteria set forth therein and as determined by the Board (or committee thereof), if applicable, and shall be eligible for any new employee benefit programs instituted by the Company for other senior executives, subject to the eligibility criteria set forth therein, as may be amended, modified or terminated from time to time.